OCUPHIRE PHARMA INC (OCUP) Stock Price, Forecast & Analysis
USA - NASDAQ:OCUP - US67577R1023 - Common Stock
OCUP Key Statistics, Chart & Performance
The current stock price of OCUP is 1.17 USD. In the past month the price decreased by -9.3%. In the past year, price decreased by -57.61%.
OCUP Latest News, Press Relases and Analysis
OCUP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.37 | 881.75B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.11B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.37 | 252.91B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.01 | 242.76B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.24 | 208.84B | ||
| MRK | MERCK & CO. INC. | 9.53 | 209.64B | ||
| PFE | PFIZER INC | 7.63 | 138.81B | ||
| SNY | SANOFI-ADR | 11.18 | 119.10B | ||
| GSK | GSK PLC-SPON ADR | 7.76 | 94.32B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7 | 93.52B | ||
| ZTS | ZOETIS INC | 19.22 | 53.99B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 194.34 | 42.96B |
Related stock screener links
About OCUP
Company Profile
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The firm is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.
Company Info
OCUPHIRE PHARMA INC
37000 Grand River Ave., Suite 120
Farmington Hills MICHIGAN 48335 US
CEO: Mina Sooch
Employees: 14
Phone: 12486819815
OCUPHIRE PHARMA INC / OCUP FAQ
What does OCUPHIRE PHARMA INC do?
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The firm is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.
What is the current price of OCUP stock?
The current stock price of OCUP is 1.17 USD. The price decreased by -12.03% in the last trading session.
What is the dividend status of OCUPHIRE PHARMA INC?
OCUP does not pay a dividend.
How is the ChartMill rating for OCUPHIRE PHARMA INC?
OCUP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the number of employees for OCUPHIRE PHARMA INC?
OCUPHIRE PHARMA INC (OCUP) currently has 14 employees.
Can you provide the market cap for OCUPHIRE PHARMA INC?
OCUPHIRE PHARMA INC (OCUP) has a market capitalization of 30.65M USD. This makes OCUP a Nano Cap stock.
OCUP Technical Analysis
OCUP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to OCUP. No worries on liquidiy or solvency for OCUP as it has an excellent financial health rating, but there are worries on the profitability.
OCUP Financial Highlights
Over the last trailing twelve months OCUP reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -165.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.46% | ||
| ROE | -34.71% | ||
| Debt/Equity | 0 |
OCUP Forecast & Estimates
9 analysts have analysed OCUP and the average price target is 17.09 USD. This implies a price increase of 1360.26% is expected in the next year compared to the current price of 1.17.
For the next year, analysts expect an EPS growth of -85.94% and a revenue growth -44.06% for OCUP